Search clinical trials for: MK-6072

Total 1742 results

Merck Sharp & Dohme LLC

Completed

A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002) (MODIFY II)

Clostridium Difficile Infection
Merck Sharp & Dohme LLC

Completed

A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001) (MODIFY I)

Clostridium Difficile Infection
Merck Sharp & Dohme LLC

Completed

Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001) (MODIFY III)

Clostridium Difficile Infection

United States, Argentina, Brazil, Colombia, Czechia, Germany, Hungary, Malaysia, Mexico, Norway, Poland, Portugal, Romania, South Africa, Spain, Sweden, United Kingdom
Ligand Pharmaceuticals

Completed

A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Alkermes, Inc.

Completed

A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia

Schizophrenia

United States
Alkermes, Inc.

Completed

An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)

Schizophrenia

United States, Bulgaria, Korea, Republic of, Malaysia, Philippines, Romania, Russian Federation, Ukraine
KBP Biosciences

Completed

Safety, Tolerability and Pharmacokinetics of KBP-7072

Healthy

United States
KBP Biosciences
Parexel

Completed

Study of KBP-7072 in Healthy Male and Female Subjects

Healthy Subjects

United States
Alkermes, Inc.

Completed

A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)

Schizophrenia

United States, Bulgaria, Korea, Republic of, Malaysia, Philippines, Romania, Russian Federation, Ukraine
Ligand Pharmaceuticals

Completed

Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus (L6972-02)

Type 2 Diabetes Mellitus

United States
KBP Biosciences

Completed

A Multiple Ascending Dose Study of KBP-7072 in Healthy Subjects

Healthy

United States
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 60732 in Healthy Male Volunteers

Healthy
Molecular NeuroImaging

Completed

Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in AD Subjects Compared to HVs.

Alzheimer's Disease

United States
Molecular Insight Pharmaceuticals, Inc.

Completed

Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents

Prostate Cancer

United States
Merck Sharp & Dohme LLC

Terminated

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Neoplasms Malignant
Ligand Pharmaceuticals
Medpace, Inc.

Completed

A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation

Type 2 Diabetes Mellitus (T2DM)

United States
Merck Sharp & Dohme LLC

Completed

A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)

Type 2 Diabetes Mellitus
C.B. Fleet Company, Inc.

Completed

Study of Efficacy of Bowel Preparation Before Colonoscopy

Bowel Cleansing Prior to Colonoscopy

United States
Novo Nordisk A/S

Recruiting

A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood

Healthy Volunteers | Dyslipidaemia

United States
Sarepta Therapeutics, Inc.
United States Department of Defense

Completed

Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus

Ebola Hemorrhagic Fever

United States
Merck Sharp & Dohme LLC

Completed

A Single Rising Dose Study of MK-8150 (MK-8150-001)

Hypertension | Isolated Systolic Hypertension (ISH)
Abbott

Completed

Evaluation of the Bioavailability of Two ABT-072 Tablet Formulations as Compared to ABT-072 Capsule Formulation

Hepatitis C

United States
Molecular Insight Pharmaceuticals, Inc.
National Cancer Institute (NCI)

Withdrawn

A Pilot Study of 123I-MIP-1072 SPECT/CT Imaging With Optional Compact Gamma Camera Probe Imaging in Men With Prostate Cancer Undergoing Prostatectomy

Prostate Cancer

United States
Ligand Pharmaceuticals
Medpace, Inc.; Beckloff Associates, Inc.

Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
TaiMed Biologics Inc.

Terminated

Study of the Safety, Tolerability and Pharmacokinetics of TMB-607 in HIV-Negative Volunteers

Human Immunodeficiency Virus

United States
Abbott
Abbott Japan Co.,Ltd

Completed

A Study of Single Doses of ABT-072 in Japanese Healthy Male Adults

Hepatitis C

Japan
Abbott

Completed

Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072

Hepatitis C

United States
Merck Sharp & Dohme LLC

Completed

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

Schizophrenia

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effects of Single Doses of MK-1064 and MK-6096 on Polysomnography (PSG) (MK-1064-003)

Polysomnography
Merck Sharp & Dohme LLC

Completed

A Single Dose Study of MK-8266 (MK-8266-001)

Hypertension
Merck Sharp & Dohme LLC

Completed

A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004)

Hepatitis C Virus Infection
Merck Sharp & Dohme LLC

Completed

Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)

Solid Tumors

United States, Canada, Switzerland
Merck Sharp & Dohme LLC

Recruiting

A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

Pulmonary Arterial Hypertension | Hypertension, Pulmonary

United States, Argentina, Australia, Belgium, Canada, Colombia, France, Germany, Israel, Italy, Mexico, New Zealand, Poland, Sweden, Turkey, United Kingdom, Greece, Russian Federation
Merck Sharp & Dohme LLC

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005)

Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC

Completed

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150 (MK-8150-002)

Hypertension | Isolated Systolic Hypertension
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)

Advanced Cancer
Merck Sharp & Dohme LLC

Recruiting

Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

HIV | HIV Pre-exposure Prophylaxis

United States, South Africa, Israel
Merck Sharp & Dohme LLC

Completed

A Multiple Dose Study of MK-3614 (MK-3614-002)

Hypertension
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-3281 in Healthy and Hepatitis C Infected Male Participants (MK-3281-002)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)(COMPLETED)

Type 2 Diabetes
Med-El Corporation

Recruiting

Expanded Indications in the Pediatric BONEBRIDGE Population

Hearing Loss, Conductive | Hearing Loss, Mixed

United States
Merck Sharp & Dohme LLC

Withdrawn

A Single-Dose Study of MK-8351 in a Lung Allergen Challenge (MK-8351-003)

Asthma
Merck Sharp & Dohme LLC

Recruiting

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Richter Transformation Lymphoma

Poland, United States, Canada, Chile, China, Estonia, Israel, Italy, Korea, Republic of, Spain, Sweden, Turkey, Czechia, Germany, Brazil, Portugal, Ireland, Singapore, United Kingdom, Japan, Peru
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)

Ulcerative Colitis

United States, Georgia, Germany, Hungary, Moldova, Republic of, Poland, Ukraine, United Kingdom
Merck Sharp & Dohme LLC

Completed

A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)

Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC

Completed

A Study of the Effect of MK-8457 on Blood Pressure in Hypertensive Participants (MK-8457-004-AM1)

Hypertension

United States
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma

Asthma

United States, Australia, New Zealand, South Africa
Merck Sharp & Dohme LLC

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)

Hepatitis C
AbbVie (prior sponsor, Abbott)

Completed

A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies

Hepatitis C Virus Infection

United States
Merck Sharp & Dohme LLC

Completed

A Two-part Study of the Effects of MK-1029 in Allergen-Challenged Asthmatics (MK-1029-003)

Asthma

3

Subscribe